AstraZeneca: IMFINZI Plus Bevacizumab Met Primary Endpoint for Progression-Free Survival in Liver Cancer Eligible for Embolization in EMERALD-1 Phase III Trial
November 10, 2023
November 10, 2023
WILMINGTON, Delaware, Nov. 10 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) in combination with transarterial chemoembolization (TACE) and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TACE alone in patients with hepatocellul . . .
Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca's IMFINZI(R) (durvalumab) in combination with transarterial chemoembolization (TACE) and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) versus TACE alone in patients with hepatocellul . . .